Economic evaluation of monoclonal antibody in the management of colorectal cancer
Journal Title: Journal of Cancer Research & Therapy - Year 2013, Vol 1, Issue 1
Abstract
Objective: This study aims to determine the cost of colorectal cancer (CRC) management and compare the cost effectiveness of cetuximab and bevacizumab in the management of CRC. Method: This economic evaluation study from a societal perspective involves collecting resource utilization data based on the clinical pathway of colorectal cancer management. The cost calculated includes drugs, human resources, administrative, investigations as well as capital cost. Patient’s cost was also calculated based on an interview with colorectal cancer patients. Effectiveness estimates for monoclonal antibody (cetuximab and bevacizumab) treatment were modeled from study respondents based on references from other studies. Results: Cost of treating a case of colorectal cancer in stage I is RM13,623 (RM12,467-RM14,777), stage II RM19,753 (RM16,734-RM23,520), stage III RM24,972 (RM20,291-RM29,654) and stage IV RM27, 163 (RM23, 192-RM31,133). Cost of CRC management increase with the increasing stage of the disease (Kruskal Wallis, X2=106, p<0.001). Based on estimates of 2671 new cases of CRC, the incremental cost of cetuximab is RM20, 556 480 and bevacizumab is RM7,557,953 at 50% stage III and IV as compared to the conventional chemotherapy. The incremental cost per quality adjusted life years gained for cetuximab is RM38,869 and RM14,290 for bevacizumab. Although both types of monoclonal antibody are considered cost effective (based on WHO guidelines of less than three times of GDP), bevacizumab is considered more cost effective than cetuximab. Cost effectiveness was sensitive to the percentage of late stages of CRC. Conclusions: Cost of treating late stage of CRC is high and bevacizumab are more cost effective compared to cetuximab in the management of the late stage of CRC.
Authors and Affiliations
Ezat SW, Natrah MS, Aljunid S, Rizal MA, Saperi S, Ismail S, Fuad I, Azrif MA
Keywords
Related Articles
- EP ID EP549497
- DOI 10.14312/2052-4994.2013-5
- Views 63
- Downloads 0
Combined treatment of gemcitabine with indole-3-carbinol or metformin on drug efficacy in pancreatic cancer cell lines: The role of human equilibrative nucleoside transporters
Pancreatic cancer is one of the most lethal carcinomas in the United States. In accord with the American Cancer Society pancreatic cancer is anticipated to move from the third to the second leading cause of deaths in the...
Pseudocystic pheochromocytoma: An incidental finding and a rare entity
Cystic adrenal neoplasms are uncommon and may be incidentally discovered during radiologic procedure not directly performed for the evaluation of adrenal disease. Cystic pheochromocytomas are uncommon neoplasms that orig...
Advance care planning in patients with brain tumours: A prospective cohort study
Objectives: To assess and understand the awareness and experience of brain tumour (BT) patients in discussing Advance Care Planning (ACP), to identify main symptoms experienced, physical and functional status perceived q...
Contributions of stochastic events to biological evolution and cancer
Stochastic genetic and epigenetic events have been fundamental in contributing to the development of manifold life-forms, past and present. The development of malignant cell clones and the role of stochasticity as a driv...
Ecological model links proto-oncogene to high incidence of metastatic cancers in African-Americans
Cancers identified by the uncontrolled proliferation of the TRPV6 mRNA biomarker, kill African-Americans (AAs) at nearly twice the rate of Whites. Malignancies assigned to this class include: Metastatic prostate cancer,...